Systemic absorption of clindamycin following intravaginal application of clindamycin phosphate 1% cream.
The extent to which clindamycin is absorbed systemically following intravaginal application of clindamycin phosphate 1% cream was assessed in 12 healthy female volunteers. Each subject received a single intravenous dose of clindamycin phosphate sterile solution (48 mg). A week later, each subject received 50 mg (5 mL) doses of intravaginal cream according to one of two dosage regimens: once daily (qd) for seven consecutive doses or twice daily (q12hr) for 13 consecutive doses. Steady state was achieved on or before day 4 for both regimens. The absolute bioavailabilities of the two intravaginal treatments were 6% for qd dosing and 13% for q12hr dosing, indicating that only a small fraction of the intravaginal dose is absorbed systemically.
Borin
M T
MT
Clinical Pharmacokinetics Unit, Upjohn Company, Kalamazoo, Michigan 49001.
D000282:Administration, Intravaginal; D000328:Adult; D001682:Biological Availability; D002981:Clindamycin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D011897:Random Allocation
D002981:Clindamycin